Jim Simons Unity Biotechnology, Inc. Transaction History

Renaissance Technologies LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$0.4 - $4.27 $249,860 - $2.67 Million	624,651 Added 65.22%	1,582,369 $625,000
Q2 2022 Aug 12, 2022	BUY	$0.56 - $1.29 $28,561 - $65,793	51,003 Added 5.63%	957,718 $540,000
Q1 2022 May 13, 2022	SELL	$0.72 - $1.86 $123,109 - $318,032	-170,985 Reduced 15.87%	906,715 $1.02 Million
Q4 2021 Feb 11, 2022	BUY	$1.3 - $3.17 $568,100 - $1.39 Million	437,000 Added 68.21%	1,077,700 $1.57 Million
Q3 2021 Nov 12, 2021	BUY	$2.91 - $4.5 $372,771 - $576,450	128,100 Added 24.99%	640,700 $1.92 Million
Q2 2021 Aug 13, 2021	BUY	$4.15 - $6.3 $2.13 Million - $3.23 Million	512,600 New	512,600 $2.38 Million
Q3 2020 Nov 13, 2020	SELL	$2.94 - $12.43 $825,846 - $3.49 Million	-280,900 Closed	0 $0
Q2 2020 Aug 13, 2020	BUY	$5.28 - $9.67 $720,720 - $1.32 Million	136,500 Added 94.53%	280,900 $2.44 Million
Q1 2020 May 14, 2020	BUY	$5.0 - $7.6 $572,000 - $869,440	114,400 Added 381.33%	144,400 $838,000
Q4 2019 Feb 13, 2020	BUY	$5.99 - $8.38 $179,700 - $251,400	30,000 New	30,000 $216,000

4.41M

Ticker UBX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 14,036,200
Market Cap $20.6M
Description
Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase II clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular d...

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.